About
Commitment to Innovation
Next-Generation CDK Therapies for Cancers Beyond CDK4/6
Restoring durable cell-cycle and transcriptional control in RB-independent, p53-mutant, KRAS-mutant, and treatment-resistant malignancies
Next-Generation CDK Therapies for Resistant Cancers
SPV Therapeutics, Inc. is advancing next-generation, precision cyclin-dependent kinase (CDK) therapies designed to restore durable control of cell-cycle and transcriptional dysregulation in cancers that adapt beyond the therapeutic reach of first-generation CDK4/6 inhibitors.
Built on Nobel Prize–recognized CDK biology, SPV develops balanced, multi-node CDK strategies to address RB-independent, p53-mutated, and treatment-resistant malignancies—disease settings in which conventional CDK4/6 inhibition often shows limited durability.
Headquartered in Research Triangle Park—one of the world’s leading life-science and innovation hubs—SPV operates at the intersection of cancer biology, medicinal chemistry, and translational science, with a singular focus on delivering more durable and inclusive treatment options for patients with hard-to-treat cancers, including triple-negative breast cancer (TNBC) and small-cell lung cancer (SCLC).